MabionCD20® Compared to MabThera® in Lymphoma Patients
Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to demonstrate the high level of biosimilarity between MabionCD20
(MABION SA) and the reference product: MabThera (rituximab by Hoffman-La Roche) in patients
with CD20-positive diffuse large B-cell lymphoma.